Bios Life

About Bios Life

Bios Life is an AI-native cancer surveillance company that emerged from stealth in August 2026 with $25 million in seed funding. The financing was led by Redmile, Vsquared Ventures, and Kindred Capital. The company is establishing a virtual clinic to offer a continuous and personalized approach to cancer screening, surveillance, and survivorship care, specifically targeting cancer survivors and individuals at high risk. This direct-to-consumer platform aims to address a gap in the current healthcare system, where these groups often receive fragmented and reactive care. The company was founded by veterans of BioNTech. Co-founder and CEO Ryan Richardson was the former Chief Strategy Officer at BioNTech and Chairman of its AI subsidiary, InstaDeep. He is joined by co-founder and COO Zach Taylor, a former Senior Vice President at BioNTech, and co-founder and Chief Medical Officer Dr. Logan Frank, a board-certified radiologist who was previously the Director of Breast Radiology at the University of Missouri. The leadership team's experience at the forefront of cancer therapy development informed their recognition of the gap between treatment advancements and the capabilities for early disease detection. Bios Life's core offering is a predictive care platform accessible via a mobile app, which is scheduled for a regional launch in the US during the second half of 2026. The platform creates a 'digital twin' for each user—a dynamic, continuously updated model of their biology based on genomic, clinical, and lifestyle data. This enables a personalized surveillance strategy that moves away from single screening events toward integrated, lifelong monitoring. The platform is powered by advanced multi-modality foundation models and is supported by clinician-led care teams of oncology nurse practitioners, an oncologist, and an internal medicine physician who guide clinical decisions based on the AI's outputs. To develop its predictive models, Bios Life has formed a multi-year strategic alliance with Tempus, giving it access to a vast de-identified multi-modal oncology dataset. The company also holds commercial rights to the Nucleotide Transformer model, an AI model developed by InstaDeep capable of analyzing the impact of genetic variations. Through a collaboration with Ambry Genetics, a Tempus company, the platform will integrate genetic screening for preventive care and survivorship programs. Keywords: cancer surveillance, virtual clinic, AI-native healthcare, cancer screening, survivorship care, personalized medicine, digital twin, predictive care, oncology AI, high-risk cancer screening, BioNTech, Tempus, genetic screening, mobile health, early cancer detection, multi-modal AI, preventative oncology, direct-to-consumer healthcare, precision medicine, genomic AI